Search results
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday? - Mustang Bio (NASDAQ:MBIO)
Benzinga· 7 days agoMustang was founded by Fortress Biotech Inc FBIO. Monday, the cell therapy-focused company announced...
Sharing hope for a cure against cancer
KGTV San Diego· 2 days agoIt has been 12 years since Emily Whitehead became the first child ever cured of cancer using CAR-T cell therapy. Emily and her father, Tom Whitehead,...
T-cell manufacturing: When is the right time to automate?
Clinical Trials Arena via Yahoo Finance· 6 days agoAdvances in automation in T-cell production are beginning to help make life-changing therapies more...
The Petri Dish: Gamida emerges from bankruptcy, InduPro’s Series A investment - Boston Business...
The Business Journals· 4 days agoGamida Cell has gathered new capital as it comes out of bankruptcy, and InduPro raised a Series A....
BrainStorm appoints new COO ahead of ALS study By Investing.com
Investing.com· 4 days agoBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a developer of adult stem cell therapies for...
'Unprecedented' CAR-T results for lupus net Insight prize for researchers
FierceBiotech· 3 days agoTwo scientists whose work sparked industry excitement about the prospect of using chimeric antigen...
Coeptis Therapeutics (NASDAQ:COEP) Lowered to Hold at LADENBURG THALM/SH SH
ETF DAILY NEWS· 2 days agoLADENBURG THALM/SH SH lowered shares of Coeptis Therapeutics (NASDAQ:COEP – Free Report) from a strong-buy rating to a hold rating in a report published on Tuesday, Zacks.com reports. Coeptis ...
Combination Targeted Treatment Produces Lasting Remissions in People with Resistant Aggressive...
Sierra Sun Times· 3 days agoCombination therapy developed by NIH researchers demonstrates the power of precision medicine. June...
Regeneron touts success with bispecific antibody in multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 6 days agoRegeneron has released encouraging trial results for its multiple myeloma antibody, linvoseltamab....
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
MedPage Today· 5 days agoHigh-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line
